Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English
News18 » Business
1-min read

Biocon Profits Rise By 72% to Rs 206.3 Crore in First Quarter Earnings

Consolidated total income of the company stood at Rs 1,490 crore for the quarter under consideration as against Rs 1,192.6 crore for the same period year ago.

PTI

Updated:July 26, 2019, 2:03 PM IST
facebookTwitterskypewhatsapp
Biocon Profits Rise By 72% to Rs 206.3 Crore in First Quarter Earnings
File image of biocon chief Kiran Mazumdar Shaw. (Image: Reuters)
Loading...

New Delhi: Biotechnology major Biocon on Thursday reported a 72.34 per cent rise in consolidated net profit to Rs 206.3 crore for the quarter ended on June 30, 2019 mainly on account of robust growth of biologics and small molecules segments.

The company had posted a net profit of Rs 119.7 crore for the corresponding period of the previous fiscal, Biocon said in a filing to BSE.

Consolidated total income of the company stood at Rs 1,490 crore for the quarter under consideration as against Rs 1,192.6 crore for the same period year ago.

"Robust performance by our biologics and small molecules business segments fuelled the 25 per cent growth in Q1 FY20 revenue to Rs 1,490 crore," Biocon Chairperson & MD Kiran Mazumdar-Shaw said.

Company's long-term investments in biosimilars are delivering expected results as demonstrated by the 96 per cent growth in its biologics revenue at Rs 490 crore this quarter, led by the expansion of geographical footprint and increased penetration of products in key developed and emerging markets, she added.

"Molecules revenue at Rs 480 crore was driven by steady API sales and a multi-fold growth in generic formulations. Our research services business continues to provide profitable growth," Mazumdar-Shaw said.

In a separate filing the company said, its board has approved the appointment of Mayank Verma as the company secretary and compliance officer.

Shares of Biocon Ltd closed at Rs 238.55 per scrip on BSE, up 0.17 per cent from its previous close.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Subscribe to Moneycontrol Pro and gain access to curated markets data, trading recommendations, equity analysis, investment ideas, insights from market gurus and much more. Get Moneycontrol PRO for 1 year at price of 3 months. Use code FREEDOM.

Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwitterskypewhatsapp
Most Active
Company Price Change %Gain
20 Microns 32.95 -3.51
Hexaware Tech 381.65 1.09
Atul 3,541.05 -2.26
Amrutanjan Heal 290.20 0.80
Company Price Change %Gain
Reliance ETF PS 269.05 -2.63
ABB India 1,359.15 -0.37
Aegis Logistics 202.25 0.07
Amara Raja Batt 612.15 -1.26
Ambalal Sarabha 12.25 -0.08

Live TV

Loading...
Countdown To Elections Results
To Assembly Elections 2018 Results